At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 61 enrolled
Drug / intervention
Sunitinib Malatedrug
Likely dose
Sunitinib Malate 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of Sunitinib Malate (Sutent) Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
In Brief
A Phase 2 clinical trial evaluating Sunitinib Malate for Renal Cell Cancer and Kidney Cancer. Completed, enrolled 61 participants across 1 site.
Detailed Summary
The goal of this clinical research study is to learn the effectiveness of Sutent® (sunitinib malate, SU011248) in the treatment of patients with non-clear cell renal cell cancer. The safety of sunitinib malate will also be studied.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Cell Cancer, Kidney Cancer
CountriesUnited States
CollaboratorsPfizer
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2007
First PostedApr 2007
Primary CompletionMar 2015
TodayJul 2026
First PostedApr 24, 2007
Enrollment StartMar 1, 2007
Primary CompletionMar 1, 2015
TodayJul 2, 2026
Enrollment to primary: 8 yearsPosted 19.2 years ago
Interventions
Sunitinib Malatedrug
50 mg by mouth daily for 4 weeks, then 2 weeks off.